Collaboration will support access of an innovative treatment developed for numerous aggressive cancers heavily influenced by metabolic pathways Collaboration will support access of an innovative treatment developed for numerous aggressive cancers heavily influenced by metabolic pathways
BERWYN, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the promotion of Donovan Quill to chief strategy officer, Life Sciences, and Bob Gilkin, RPh, MBA, to chief commercial and growth officer. In their new positions, Donovan and Bob serve dual appointments, continuing in their leadership roles at AscellaHealth while contributing to the growth of Actum Pharma as an affiliate organization that helps companies fund, develop, manage and market novel, life-changing therapies.
See the original post here:
AscellaHealth Announces Key Executive Promotions, Supporting Strategic Growth in the Life Sciences Business Unit
In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope
See the original post:
Virbac: In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope
Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December 31, 2024, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” (“AMF”) and its 2024 Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”).
WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence (AI), with an aim to accelerate the development of PredicTcell, the Company’s proprietary AI-driven target prediction model for precision immunotherapy.
Originally posted here:
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer.
View original post here:
Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on...
- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 -
Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease
Read the original:
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases
Read more from the original source:
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
LONDON, Ontario and BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company, today announced that the Company’s Cell Pouch Bio-hybrid Organ in clinical development as a functional cure for type 1 diabetes (T1D) will be highlighted in a panel discussion titled Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions at the 2025 Cell & Gene Meeting on the Med conference in Rome, Italy on Wednesday, April 16, 2025.